文章：

病毒载体与细胞外囊泡：CRISPR/Cas介导的癌症治疗中利用的先天递送系统

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy 

原文发布日期：2023-02-28 

英文摘要：

Gene editing-based therapeutic strategies grant the power to override cell machinery and alter faulty genes contributing to disease development like cancer. Nowadays, the principal tool for gene editing is the clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR/Cas9) system. In order to bring this gene-editing system from the bench to the bedside, a significant hurdle remains, and that is the delivery of CRISPR/Cas to various target cells in vivo and in vitro. The CRISPR-Cas system can be delivered into mammalian cells using various strategies; among all, we have reviewed recent research around two natural gene delivery systems that have been proven to be compatible with human cells. Herein, we have discussed the advantages and limitations of viral vectors, and extracellular vesicles (EVs) in delivering the CRISPR/Cas system for cancer therapy purposes. 

摘要翻译： 

基于基因编辑的治疗策略赋予人们超越细胞机制的能力，并可改变导致癌症等疾病发生的缺陷基因。目前，基因编辑的主要工具是成簇规律间隔短回文重复序列相关核酸酶9（CRISPR/Cas9）系统。为了将这一基因编辑系统从实验室推向临床，仍存在一个重大障碍——如何实现CRISPR/Cas系统在体内外多种靶细胞中的递送。目前可通过多种策略将CRISPR-Cas系统递送至哺乳动物细胞，本文重点综述了两种经证实与人类细胞兼容的天然基因递送系统的最新研究进展，分别探讨了病毒载体和细胞外囊泡（EVs）在癌症治疗领域递送CRISPR/Cas系统的优势与局限性。

原文链接：

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy